|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for OAS3 |
 Gene summary |
| Basic gene Info. | Gene symbol | OAS3 |
| Gene name | 2'-5'-oligoadenylate synthetase 3, 100kDa | |
| Synonyms | p100|p100OAS | |
| Cytomap | UCSC genome browser: 12q24.2 | |
| Type of gene | protein-coding | |
| RefGenes | NM_006187.3, | |
| Description | (2-5')oligo(A) synthase 3(2-5')oligo(A) synthetase 32'-5'-oligoadenylate synthase 32'-5'oligoadenylate synthetase p1002-5A synthase 32-5A synthetase 3p100 OAS | |
| Modification date | 20141216 | |
| dbXrefs | MIM : 603351 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000111331 | ||
| HPRD : 04519 | ||
| Vega : OTTHUMG00000169795 | ||
| Protein | UniProt: Q9Y6K5 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_OAS3 | |
| BioGPS: 4940 | ||
| Pathway | NCI Pathway Interaction Database: OAS3 | |
| KEGG: OAS3 | ||
| REACTOME: OAS3 | ||
| Pathway Commons: OAS3 | ||
| Context | iHOP: OAS3 | |
| ligand binding site mutation search in PubMed: OAS3 | ||
| UCL Cancer Institute: OAS3 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0009615 | response to virus | 19056102 | GO:0045071 | negative regulation of viral genome replication | 19056102 | GO:0051607 | defense response to virus | 19923450 | GO:0060700 | regulation of ribonuclease activity | 19923450 |
| Top |
| Ligand binding site mutations for OAS3 |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | R30 | R30Q | BLCA | 1 | K23 | E24K | SKCM | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for OAS3 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | R30 | R30Q | -1.1734849 | K23 | E24K | -1.0342651 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for OAS3 from PDB |
| Top |
| Differential gene expression and gene-gene network for OAS3 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for OAS3 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0021400 | Influenza, Human | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for OAS3 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of OAS3 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | NUC | Nucleic Acids | 4s3n | A | K23 | NUC | Nucleic Acids | 4s3n | A | R30 |
| Top |
| Conservation information for LBS of OAS3 |
| Multiple alignments for Q9Y6K5 in multiple species |
| LBS | AA sequence | # species | Species | A245 | GCKKDAFSLAE | 1 | Homo sapiens | A245 | GCGKDSFSLAQ | 1 | Mus musculus | A245 | GCRKDAFSLAQ | 1 | Rattus norvegicus | D12 | PAGALDKLVAH | 2 | Mus musculus, Rattus norvegicus | D12 | PAAALDRFVAR | 1 | Homo sapiens | D244 | QGCKKDAFSLA | 1 | Homo sapiens | D244 | QGCGKDSFSLA | 1 | Mus musculus | D244 | QGCRKDAFSLA | 1 | Rattus norvegicus | E186 | AACFTELRRNF | 1 | Homo sapiens | E186 | SACFTEPRKNF | 1 | Mus musculus | E186 | SACFTELRKNF | 1 | Rattus norvegicus | K198 | NIRPAKLKNLI | 1 | Homo sapiens | K198 | NTRPAKLKNLI | 1 | Mus musculus | K198 | NIRPVKLKNLI | 1 | Rattus norvegicus | K200 | RPAKLKNLILL | 2 | Homo sapiens, Mus musculus | K200 | RPVKLKNLILL | 1 | Rattus norvegicus | K23 | RLQPRKEFVEK | 1 | Homo sapiens | K23 | NLHPAPEFTAA | 1 | Mus musculus | K23 | SLHPAPEFTAA | 1 | Rattus norvegicus | K56 | APRVLKTVKGG | 1 | Homo sapiens | K56 | RPRVIRIAKGG | 1 | Mus musculus | K56 | RPRVIRIIKGG | 1 | Rattus norvegicus | K59 | VLKTVKGGSSG | 1 | Homo sapiens | K59 | VIRIAKGGAYA | 1 | Mus musculus | K59 | VIRIIKGGAHA | 1 | Rattus norvegicus | L55 | AAPRVLKTVKG | 1 | Homo sapiens | L55 | QRPRVIRIAKG | 1 | Mus musculus | L55 | QRPRVIRIIKG | 1 | Rattus norvegicus | N193 | RRNFVNIRPAK | 1 | Homo sapiens | N193 | RKNFVNTRPAK | 1 | Mus musculus | N193 | RKNFVNIRPVK | 1 | Rattus norvegicus | R13 | AAALDRFVARR | 1 | Homo sapiens | R13 | AGALDKLVAHN | 1 | Mus musculus | R13 | AGALDKLVAHS | 1 | Rattus norvegicus | R30 | FVEKARRALGA | 1 | Homo sapiens | R30 | FTAAVRGALGS | 1 | Mus musculus | R30 | FTAAVRRALGS | 1 | Rattus norvegicus | R53 | GAAAPRVLKTV | 1 | Homo sapiens | R53 | GSQRPRVIRIA | 1 | Mus musculus | R53 | GLQRPRVIRII | 1 | Rattus norvegicus | T57 | PRVLKTVKGGS | 1 | Homo sapiens | T57 | PRVIRIAKGGA | 1 | Mus musculus | T57 | PRVIRIIKGGA | 1 | Rattus norvegicus | V54 | AAAPRVLKTVK | 1 | Homo sapiens | V54 | SQRPRVIRIAK | 1 | Mus musculus | V54 | LQRPRVIRIIK | 1 | Rattus norvegicus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |